This article has been updated to include comments from NeoGenomics' earnings call.

NEW YORK (GenomeWeb) – NeoGenomics today reported a 142 percent increase in its third quarter revenues on continued growth in clinical genetic testing volume, driven by its acquisition of Clarient.

For the three-month period ended Sept. 30, the company's revenues increased to $60.8 million from $25.1 million in the same period last year, falling just short of analysts' consensus estimate of $61 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.